256 related articles for article (PubMed ID: 23383079)
41. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
[TBL] [Abstract][Full Text] [Related]
42. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
43. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
44. [Cohort Study of EGFR-TKIs Combined with Traditional Chinese Medicine and Single EGFR-TKIs for Advanced NSCLC (Non₋small Cell Lung Cancer)].
Xiong SQ; Li YL; Wang SM; Jin S; Luo QY; Ding Q; Song TT; Wang LJ; Cai R; Lü PP; He CS; Xiang J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):566-569. PubMed ID: 30378311
[TBL] [Abstract][Full Text] [Related]
45. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
46. [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis].
Cao F; Zhang L; Wang S; Zhong D; Wang Y
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):146-54. PubMed ID: 25800570
[TBL] [Abstract][Full Text] [Related]
47. Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients.
Tanaka H; Atagi K; Tatsumichi T; Yamaguchi K; Takahashi K; Kaji M; Kosaka S; Houchi H
J Chemother; 2020 Apr; 32(2):83-87. PubMed ID: 31957595
[TBL] [Abstract][Full Text] [Related]
48. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
49. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
50. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials.
Alimujiang S; Zhang T; Han ZG; Yuan SF; Wang Q; Yu TT; Shan L
Asian Pac J Cancer Prev; 2013; 14(4):2413-9. PubMed ID: 23725150
[TBL] [Abstract][Full Text] [Related]
52. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
53. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
54. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
55. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
56. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
[TBL] [Abstract][Full Text] [Related]
57. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
58. Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.
La Salvia A; Rossi A; Galetta D; Gobbini E; De Luca E; Novello S; Di Maio M
Clin Lung Cancer; 2017 Jan; 18(1):23-33.e1. PubMed ID: 27876230
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials.
Liu R; Wei S; Zhang Q; Zhang X; Luo H; Tian J; Li Y; Ge L; Wang X
Medicine (Baltimore); 2019 Jul; 98(29):e16427. PubMed ID: 31335695
[TBL] [Abstract][Full Text] [Related]
60. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]